Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells

    loading  Checking for direct PDF access through Ovid


In patients with advanced colorectal cancer (CRC), surgery is complemented with systemic therapy – chemotherapy and radiochemotherapy. Although the patients’ overall survival has been significantly improved, tumor resistance is still a frequent cause of chemotherapy failure. Several factors contribute to chemoresistance of tumor cells including changes related with epithelial-mesenchymal transition (EMT). The present study was designed to verify the presence of EMT markers in paired CRC primary cell lines obtained from primary tumor sites and lymph node metastases of three patients and to investigate the effect of irinotecan and oxaliplatin treatment on these markers as well. The samples of the higher stage of CRC and positive for angioinvasion were selected and qPCR, western blot analysis, migration assay, cytotoxicity testing was performed.Results confirmed the increased expression of several markers characteristic of EMT and invasiveness in lymph node metastatic cells, with a significant variability between individual samples. Irinotecan and oxaliplatin decreased migration activity of the cells and to the varying degree affected the expression of EMT and invasiveness markers. In conclusion, in CRC EMT is present in metastatic cells over a phenotypic continuum whose expression is altered heterogeneously upon irinotecan and oxaliplatin treatment.HighlightsSignificant variability and lower expression uniformity in lymph node metastatic cells.Heterogeneity of cell response partially determined by cancer cell microenvironment.Metastatic cells proved to be less sensitive to chemotherapy treatment compared to primary site cancer cells.Irinotecan and oxaliplatin affected EMT markers in primary cell lines.

    loading  Loading Related Articles